Incyte | Eiendeler

Created with Highcharts 10.1.0Chart context menu4.46B4.89B5.39B5.88B6.38B6.87B7.3B
2022Q32023Q32024Q3


Assets Endring Dato
Acadia Pharmaceuticals USD 1.19B 210.89M 2024-12
Agios Pharmaceuticals USD 1.66B 128.6M 2024-12
Alnylam Pharmaceuticals USD 4.24B 34.94M 2024-12
Amgen USD 91.84B 956M 2024-12
Biogen USD 28.05B 263.9M 2024-12
BioMarin Pharmaceutical USD 6.99B 137.74M 2024-12
Bristol-Myers Squibb USD 92.6B 1.07B 2024-12
Eli Lilly USD 78.71B 3.11B 2024-12
Exelixis USD 2.95B 12.59M 2025-01
Gilead Sciences USD 59B 4.47B 2024-12
Incyte USD 5.44B 431.89M 2024-12
Ionis Pharmaceuticals USD 3B 77.42M 2024-12
MacroGenics USD 264.49M 63.36M 2024-09
Merck USD 117.11B 426M 2024-12
Moderna USD 14.14B 1.66B 2024-12
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 213.4B 6.08B 2024-12
PTC Therapeutics USD 1.71B 137.21M 2024-12
Regeneron Pharmaceuticals USD 37.76B 317.5M 2024-12
Sarepta Therapeutics USD 3.96B 363.24M 2024-12
Ultragenyx Pharmaceutical USD 1.5B 34.91M 2024-12
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



Incyte Eiendeler - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.